| Bioactivity | Devimistat (CPI-613) is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells[1]. | ||||||||||||
| Invitro | Devimistat induces apoptosis of GPM-2 gastric cancer cells. Devimistat targets the altered form of mitochondrial energy metabolism utilized by tumor cells. The change in mitochondrial enzyme activities and cellular redox status induced by devimistat leads to cell death, including apoptosis[1]. | ||||||||||||
| Name | Devimistat | ||||||||||||
| CAS | 95809-78-2 | ||||||||||||
| Formula | C22H28O2S2 | ||||||||||||
| Molar Mass | 388.59 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Devimistat
CAS: 95809-78-2 F: C22H28O2S2 W: 388.59
Devimistat (CPI-613) is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mito
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.